The Future of mCRPC Treatment: Integrating Genetic and Genomic Testing

Prostate cancer is the second most common cancer in men, with more than 1.4 million new cases and...

Webinar Overview: Challenges of Liquid Biopsy Assay Validation and Quality Control

Liquid biopsy testing has been widely adopted to support early cancer diagnosis, therapy selection,...

Is ctDNA the Secret to Noninvasive Detection & Treatment of Lymphoma?

Nearly 5% of all cancer diagnoses in the U.S. are lymphoma. This cancer of the lymphatic system...

Biofidelity Customer Case Study

Premium reference materials help take innovative genomic technology into the clinic Biofidelityis...

Ideal Samples for Validating Next-Generation Sequencing-Based Plasma Circulating Tumor DNA Assays

Over the past decade, liquid biopsy-based testing, especially using next-generation sequencing...

Copy That! Detecting Copy Number Variation in Disease Using Next Generation Sequencing

If one of your colleagues suggests including copy number variations (CNVs) in your assay that...

How to get the most from your Seraseq® FFPE Reference Materials

Most tumor profiling assay workflows use tissue biopsy samples that are formalin fixed and paraffin...

When a Bad Repair Leads to a Happy Ending: Homologous Recombination Deficiency Assays for Guiding Anti-Cancer Therapies

Genome instability - in which tumor cells sustain elevated frequencies of chromosomal lesions - is...

Optimal Reference Materials for Evolving Oncology Testing

Targeted therapies are dramatically improving cancer treatment. Next-generation sequencing (NGS)...

Are your BRCA1/2 tests sufficient?

Breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) encode proteins functioning as tumor...